Antigen/antibody reaction
One of the newer mechanisms to consider is the
antigen/antibody reaction. In this case, highly purified radiolabeled monoclonal
antibodies with high specificity for a particular antigen are injected
intravenously and imaged at a later point in time, often 1-3 days post
injection. For example, In-111 Oncoscint CR/OV, a monoclonal antibody specific
for TAG-72.3, a tumor-associated glycoprotein expressed by colorectal and
ovarian carcinomas, has been very useful in evaluating recurrence of these
diseases. There are a variety of these radiolabeled antibodies in clinical
trials, both diagnostic and therapeutic, for a wide variety of diseases
such as lung carcinoma, prostate and breast cancer, and venous thrombosis.
Stephen Karesh, PhD. |
Last Updated: August 14, 1996 |